2026
Top Global Biosecurity Risks
Biosecurity in 2026 is no longer mainly a laboratory, health-ministry, or defence issue. It has become a board-level resilience challenge shaped by zoonotic disease, fragile global preparedness, AI-enabled life sciences, cyber exposure, and geopolitical fragmentation.
The new reveal is this: the most consequential biosecurity risk may not be a single engineered pathogen or a single outbreak. It is the growing gap between how quickly biological threats can emerge, be amplified, or be misunderstood and how slowly institutions, supply chains, surveillance systems, and international agreements respond.
For decision-makers, the uncomfortable contrast is clear. The world has more powerful capabilities to detect pathogens, design diagnostics, develop vaccines, and analyse biological data than ever before. Yet it is also operating in a more fragmented environment for sharing samples, data, expertise, financing, and public trust. In 2026, biological resilience depends as much on governance and operational readiness as on science.
Why 2026 is different
The risks below overlap. A zoonotic outbreak can disrupt food systems and trade; a cyberattack can blind a laboratory network during an outbreak; misinformation can undermine vaccination or public-health action; and AI can simultaneously improve scientific response while lowering barriers to misuse.
The World Economic Forum’s 2026 outlook puts geopolitical and geoeconomic confrontation at the centre of near-term global risk. That context matters for biosecurity because it makes cross-border cooperation, supply-chain resilience, scientific exchange, and coordinated emergency response harder precisely when they are most needed.
Meanwhile, the World Health Organization’s Pandemic Agreement, adopted in May 2025, has not yet reached its full operational potential. Negotiations on the critical Pathogen Access and Benefit Sharing – PABS – annex continued through 2026. The annex is intended to enable rapid sharing of pathogens and genomic data while ensuring more equitable access to the vaccines, diagnostics, and therapeutics that result. Its incompleteness illustrates the central vulnerability: governance has not yet caught up with the speed and interdependence of biological risk.
The major risks
| Risk | Why it matters in 2026 | What leaders should watch |
|---|---|---|
| Zoonotic spillover and pandemic emergence | Human, animal, and environmental health remain tightly connected. H5N1’s continued spread in animal populations shows why surveillance cannot be limited to hospitals and human cases. | Animal mortality signals, cross-species infections, delayed genomic sequencing, weak veterinary-public-health data sharing |
| Fragile surveillance and response capacity | Outbreaks become crises when detection, diagnostic confirmation, contact tracing, clinical care, and communications are delayed or disconnected. | Gaps in wastewater, genomic, veterinary, and syndromic surveillance; poor data interoperability; underfunded local laboratories |
| AI-enabled biological misuse | Advanced AI and engineering biology can speed legitimate discovery but may also make high-risk knowledge and experimental planning more accessible. | Weak model safeguards, insufficient screening for sensitive biological work, inadequate oversight of dual-use research |
| Accidental release and laboratory failure | High-consequence work requires more than technical containment: it needs rigorous governance, staff training, incident reporting, physical security, and cyber resilience. | Near-misses, weak inventory controls, inconsistent biosafety culture, under-resourced inspection and assurance |
| Deliberate biological threats | States and non-state actors may seek to exploit biological agents, especially in an era of geopolitical tension and asymmetric conflict. | Intelligence indicators, suspicious procurement or laboratory activity, attribution readiness, emergency public-health coordination |
| Cyber-bio convergence | Laboratories, sequencing pipelines, diagnostic platforms, hospitals, cold chains, and public-health systems increasingly depend on interconnected software and operational technology. | Ransomware, data integrity failures, compromised laboratory information systems, supplier concentration |
| Antimicrobial resistance | AMR is a slow-moving but persistent biosecurity threat, capable of turning routine infections and medical procedures into higher-risk events. | Resistance trends, inappropriate antimicrobial use, gaps in infection prevention, limited access to reliable diagnostics |
| Food, animal, and crop biosecurity | Biological threats can damage livestock, crops, food processing, and trade even when human health effects are limited. | Animal disease incursions, crop pests, import restrictions, foodborne outbreaks, gaps in cold-chain and traceability systems |
| Misinformation and loss of trust | A technically sound response can fail if populations distrust the messenger, reject protective measures, or are exposed to deliberately manipulated information. | Rumour propagation, health-worker harassment, vaccine confidence trends, adversarial use of synthetic media |
| Unequal access to countermeasures | Pathogen samples and sequence data can move quickly; vaccines, diagnostics, manufacturing capacity, finance, and delivery systems often cannot. | Concentration of manufacturing, export restrictions, procurement inequity, lack of regional fill-finish capacity |
1. Zoonotic spillover remains the front door
The most probable biological emergencies still begin in the natural world. Pathogens circulate among wildlife, livestock, companion animals, vectors, and people; land-use change, climate pressures, intensive agriculture, travel, and trade can alter the opportunities for spillover.
Highly pathogenic avian influenza A(H5N1) is the clearest 2026 illustration. WHO reported that countries in the Asia-Pacific region were confronting outbreaks in animals with potential for spillover to humans, and it stressed that effective One Health coordination, linking human, animal, and environmental health authorities, is essential to detect, characterize, and act on zoonotic threats quickly.
The opposing view is important: widespread animal outbreaks do not automatically mean an imminent human pandemic. Risk communication must avoid treating every zoonotic signal as proof that sustained human-to-human transmission is underway. However, the counterargument is stronger from a resilience perspective: the time to build integrated surveillance, laboratory capacity, and response relationships is before a pathogen acquires the characteristics that enable sustained transmission. Waiting for certainty is operationally expensive.
Decision-maker implication: build One Health intelligence into enterprise and national risk systems. For food, agriculture, logistics, insurance, travel, and consumer businesses, animal-health signals may be an earlier operational warning than human case counts.
2. Surveillance gaps turn outbreaks into strategic shocks
The world has made major advances in diagnostics, sequencing, wastewater monitoring, and digital epidemiology. But these capabilities remain unevenly distributed and often poorly connected. A local signal only protects the wider system if it is detected, validated, shared, interpreted, and converted into a decision in time.
WHO’s recent messaging on influenza surveillance captures the core point: “information that sits in a spreadsheet protect no one”; data must reach the relevant decision-maker at the moment action can still change the outcome.
This is more than a public-health issue. Organisations rely on early signals to activate continuity plans, secure critical supplies, protect staff, adjust travel policy, prepare communications, and assess revenue implications. A country may have sophisticated national analytics but still lack the last-mile laboratory, clinical, veterinary, or local-government capabilities needed to see a threat early.
Example: a major retailer or rewards platform with partners across multiple markets may be exposed less by an outbreak’s headline case total than by local restrictions, logistics disruption, reduced mobility, hospital strain, or consumer anxiety in a specific region. A resilient operating model combines official health alerts with supply-chain, partner, workforce, and customer-behaviour indicators.
3. AI and engineering biology create a dual-use challenge
AI is increasingly valuable in biology: it can support protein analysis, drug discovery, diagnostic development, literature synthesis, laboratory automation, and biosurveillance. These same advances create a governance problem. As tools become more capable, accessible, and interoperable, they can reduce cost, time, and specialist knowledge required for some high-risk biological activities.
The UK’s 2026 Biological Security Strategy implementation report explicitly warns that advances in AI and biology can give broader access to skills and knowledge for high-risk research at lower cost, increasing the risk of accidental misuse and providing hostile actors with new opportunities. UK government work on engineering biology also found that respondents identified reliability and trust in AI outputs as the largest perceived risk, followed by biosecurity and safety concerns.www+1
A realistic opposing view is that overstating AI-bio risks could impede valuable research, slow medical innovation, and create compliance burdens that favour only large incumbents. That concern is legitimate. The objective should not be to restrict biology or prohibit AI-supported science. It should be to establish proportional safeguards around the highest-consequence capabilities: evaluation, access controls, auditability, secure development practices, appropriate customer screening, and clear escalation routes.
The leadership question is not “Should we use AI in biology?” It is: “Which capabilities create material misuse risk, who can access them, what evidence demonstrates that controls work, and who is accountable if safeguards fail?”
4. Laboratory accidents and insider risk remain under-managed
Biosecurity is often discussed in terms of deliberate attack. Yet accidental release, procedural failure, inventory errors, inadequate training, maintenance lapses, and insider misconduct can be just as consequential. The risk is not limited to the highest-containment laboratories. It also exists across the wider ecosystem of research laboratories, diagnostic facilities, sample-transport networks, universities, biotechnology companies, contract research organisations, and manufacturing sites.
The UK defines biological security broadly: protection against biological risks arising naturally, through accidental release of hazardous material, or through deliberate attack, affecting people, animals, plants, or the wider environment.
The opposing view is that mature laboratories already operate under established biosafety standards and that further controls may add bureaucracy without improving safety. In many high-performing facilities, that is partly true. But compliance evidence is not the same as operational assurance. Leaders should focus less on the existence of policies and more on observable control performance:
- Are near-misses reported without fear of punishment?
- Is the biological-material inventory accurate and routinely reconciled?
- Are access rights reviewed as roles change?
- Are contractors and suppliers assessed to the same standard as internal teams?
- Are cyber incidents treated as potential biosafety incidents when they affect protocols, instruments, data, or access controls?
- Has the organisation tested incident communications with regulators, staff, customers, and local authorities?
5. Deliberate biological threats are harder to deter and attribute
The Biological Weapons Convention prohibits the development, production, acquisition, and stockpiling of biological weapons. Yet the international system still has a major structural limitation: there is no equivalent BWC implementing agency responsible for investigating alleged use. The UN Secretary-General’s Mechanism is the only international mechanism available to investigate alleged biological-weapons use.disarmament.
That does not mean a biological attack is the most likely risk. It means the potential consequences, uncertainty, attribution challenges, and political escalation risks justify serious preparation.
A common counterargument is that biological weapons are difficult to develop, deploy, control, and use predictably; therefore, they are less attractive than conventional or cyber methods. This is broadly correct, and it should temper sensationalism. But deterrence cannot rely on technical difficulty alone. The convergence of accessible biotechnology, fragmented governance, misinformation, and geopolitical conflict creates a changing risk environment.
Practical priority: develop cross-sector response arrangements before a crisis. Public health, law enforcement, intelligence, regulators, laboratories, hospitals, critical-infrastructure operators, and communications teams need shared protocols for evidence preservation, health protection, public messaging, and continuity.
6. Cyber-bio risk can disable the response itself
A biological event increasingly depends on digital infrastructure: laboratory information-management systems, electronic health records, genomic databases, diagnostic devices, cold-chain systems, supply-chain platforms, hospital networks, and national reporting systems. A cyberattack during a biological emergency could corrupt data, interrupt testing, delay treatment, expose patient information, or disrupt distribution of medical countermeasures.
The World Economic Forum ranked cyber insecurity among the leading risks in its two-year outlook, while the UK’s 2026 resilience reporting highlights rising cyberattacks on business supply chains and the destabilising potential of AI-generated misinformation.
The opposing view is that cyber resilience is already a separate corporate risk programme and does not need to be absorbed into biosecurity. That siloed approach is increasingly inadequate. The relevant question is whether a cyber incident can impair the organisation’s ability to detect, manage, communicate about, or recover from a biological threat. If it can, it belongs in biosecurity exercises and business-continuity planning.
7. Antimicrobial resistance is the chronic threat
Unlike a sudden outbreak, antimicrobial resistance – AMR – rarely creates a single dramatic news cycle. Its impact accumulates: infections become harder to treat, hospital stays lengthen, routine surgery and cancer treatment become more risky, and health systems face greater cost and capacity pressure.
AMR should be treated as a biosecurity issue because it weakens the response capacity needed for every other biological shock. In a major outbreak, the ability to prevent secondary infections and treat bacterial complications can be decisive. It also has economic consequences through absenteeism, productivity losses, higher healthcare costs, and pressure on insurance and public services.
The opposing view is that AMR is primarily a clinical and pharmaceutical-policy challenge, not a security concern. That narrow framing misses its systemic effects. For senior leaders, the security lens helps connect AMR to workforce resilience, healthcare capacity, supply chains, procurement, and global inequality.
8. Food, livestock, and crop threats can become economic crises
Biosecurity is not confined to human health. Disease in livestock, contamination of food systems, crop pathogens, invasive pests, and disruptions to animal-product trade can have rapid economic and political effects. Such events can raise prices, reduce availability, affect rural livelihoods, strain public confidence, and provoke trade restrictions.
A One Health lens is crucial because agricultural and environmental signals may provide early warning of risks that later affect human health, household budgets, business operations, and national stability. WHO’s work around H5N1 highlights this interdependence by bringing together public health, animal-health, environmental, and regional partners.
For companies, exposure may be indirect: higher commodity prices, supplier disruption, increased transport costs, food-service disruption, employee impact, or changing customer behaviour. Organisations should map critical dependencies beyond their tier-one suppliers.
9. Misinformation is a biological risk multiplier
The biological hazard may be real, but the crisis can become larger when distrust prevents protective action. Misinformation can discourage vaccination, fuel stigma, target health workers, trigger panic purchasing, discredit public institutions, or encourage unsafe self-treatment. Synthetic media and coordinated influence campaigns make this more difficult to manage.
The World Economic Forum identifies misinformation and disinformation among the most prominent near-term global risks, a finding with direct implications for public-health communication.
There is a reasonable concern that governments and companies can label legitimate criticism as “misinformation.” That risk should not be dismissed. Effective communication is not censorship; it is transparent, evidence-based engagement that acknowledges uncertainty, explains trade-offs, corrects false claims with accessible information, and avoids overclaiming.
For leaders: pre-approve crisis governance, credible spokespeople, monitoring processes, and audience-specific communications. Trust cannot be invented during the first 48 hours of a crisis.
What organisations should do now
A mature biosecurity strategy should not be a standalone technical document. It should be integrated with enterprise risk, cybersecurity, supply-chain management, workforce protection, ESG, legal, crisis communications, and executive governance.
Establish a board-level biosecurity view
Boards and executive teams should receive a concise, recurring assessment that covers:
- Material biological risks by geography, business unit, supplier base, and workforce footprint.
- Interdependencies between health events, operational technology, data systems, supply chains, and public trust.
- Clear risk appetite for research, data sharing, supplier engagement, and AI-enabled biological capabilities.
- Named executive accountability, escalation thresholds, and tested decision rights.
- Quantified scenarios, including revenue, cash-flow, workforce, supplier, regulatory, and reputational effects.
Build a One Health intelligence model
Organisations with global operations should combine relevant signals from human health, animal health, agriculture, environment, travel, logistics, and local operating conditions. This does not require every company to create an epidemiology unit. It does require clarity on:
- Which external signals matter.
- Who monitors them.
- How a signal is validated.
- Which management decision follows.
- How often the organisation rehearses its response.
Test the response, not just the plan
A plan sitting in a shared drive is not resilience. Run scenario exercises that test decisions under uncertainty. Examples include:
- A zoonotic outbreak affects a major sourcing region.
- A ransomware attack disrupts laboratory or healthcare data during an outbreak.
- A false social-media narrative targets employees, customers, or partners.
- A sudden export restriction interrupts critical medical or production inputs.
- A supplier experiences a biosafety incident and cannot disclose details immediately.
The point is not to predict the exact crisis. It is to identify whether leadership, data, communications, suppliers, and governance can function under pressure.
Govern AI and biological data responsibly
Organisations developing, procuring, or using AI in life sciences should establish proportionate controls:
- Classify biological use cases by potential consequence and misuse risk.
- Evaluate high-capability systems before deployment.
- Implement access controls, logging, monitoring, and clear human oversight.
- Conduct supplier due diligence on model providers, laboratory partners, synthesis providers, and cloud infrastructure.
- Create pathways for researchers and employees to raise concerns safely.
- Ensure security teams, biosafety experts, legal counsel, and ethics leads operate together rather than in separate approval chains.
A balanced conclusion
The central biosecurity challenge of 2026 is not that catastrophe is inevitable. It is that the global risk environment is increasingly interconnected while preparedness remains fragmented.
There are grounds for optimism. The WHO Pandemic Agreement, the work to finalize its PABS annex, improved genomic and influenza surveillance, the continuing development of AI-enabled diagnostics, and growing recognition of One Health all show that international institutions and national governments are attempting to modernise preparedness.who+2
But optimism without execution is not resilience. The gap between scientific capability and institutional readiness can widen quickly when geopolitical competition, funding pressure, cyber insecurity, and distrust constrain cooperation. Leaders should therefore treat biosecurity not as a remote health contingency, but as a strategic capability: the ability to anticipate, absorb, respond to, and recover from biological disruption while preserving trust and continuity.
How PAD US can help
PAD US can help organisations translate biosecurity uncertainty into an actionable resilience agenda. This includes executive and board risk assessments; scenario planning and crisis simulations; AI, data, and dual-use governance; cross-functional operating-model design; supply-chain and partner dependency mapping; stakeholder communications planning; and the development of measurable preparedness roadmaps. The objective is not to turn every organisation into a public-health agency, it is to ensure that leadership teams can make fast, evidence-informed decisions when biological risk affects people, operations, customers, and reputation.
Bibliography
- World Economic Forum, The Global Risks Report 2026. World Economic Forum
- World Economic Forum, Global Risks Report 2026: Geopolitical and Economic Risks Rise in New Age of Competition. World Economic Forum
- World Health Organization, WHO Member States Continue Negotiations on the Pathogen Access and Benefit Sharing Annex, 20 July 2026. WHO
- World Health Organization, WHO Member States Agree to Extend Negotiations on Pathogen Access and Benefit-Sharing Annex, 1 May 2026. WHO
- World Health Organization, Asia-Pacific Regional Influenza Network Sharpens Focus on Avian Influenza Preparedness, 27 August 2026. WHO
- UK Government, UK Biological Security Strategy: Implementation Report, July 2025–July 2026. GOV.UK
- UK Government, AI Adoption by the Engineering Biology Community: Survey Findings, 29 January 2026. GOV.UK
- UK Government, Biosecurity Frontiers, 15 April 2026. GOV.UK
- United Nations Office for Disarmament Affairs, Secretary-General’s Mechanism for Investigation of Alleged Use of Chemical and Biological Weapons. UNODA
- United Nations Office for Disarmament Affairs, The BWC at 50: African Conference Highlights Progress, Challenges and Road Ahead, 5 January 2026. UNODA
Researched and drafted with AI assistance, edited and fact-checked by the author. Illustration: AI-generated.